On Thursday, in the course of current trade, Shares of Juniper Networks, Inc. (NYSE:JNPR), climbed 1.24%, and is now trading at $27.82.
Juniper Networks, declared the Company will present at the following investor conference in August:
Kathleen Nemeth, vice president of investor relations, and Mike Marcellin, chief marketing officer, Juniper Networks, will present at the Oppenheimer 18th Annual Technology, Internet & Communications Conference, Tuesday, Aug. 11, 2015 at 9:05 a.m. ET in Boston.
Juniper Networks, Inc. designs, develops, and sells high-performance network products and services worldwide. It provides various routing products, counting ACX series universal access routers to deploy new high-bandwidth services; MX series Ethernet routers that functions as a universal edge platform; M series edge routers; PTX series packet transport routers; and T series routers.
During an Afternoon trade, Shares of Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS, climbed 5.26%, and is now trading at $1.40.
Sunesis Pharmaceuticals, stated financial results for the second quarter ended June 30, 2015. Loss from operations for the three and six months ended June 30, 2015 was $10.6 million and $19.4 million, respectively. As of June 30, 2015, cash, cash equivalents and marketable securities totaled $39.6 million.
“We remain committed to moving vosaroxin forward as an important new therapy for patients with AML, and to realizing the value of this product candidate for all our constituents,” said Daniel Swisher, Chief Executive Officer of Sunesis. “As part of this effort, we are moving forward rapidly toward the filing of a marketing authorization application in Europe and are carefully evaluating and refining our plans to gain marketing approval in the U.S. As we continue to advance these strategies and work toward key milestones with our kinase inhibitor pipeline, we are also evaluating and precedingitizing our spending to ensure our ability to realize the value of our portfolio.”
Sunesis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of oncology therapeutics for the treatment of solid and hematologic cancers.
Finally, DTE Energy Co (NYSE:DTE), gained 0.11% Thursday.
DTE Energy, stated second quarter 2015 earnings of $109 million, or $0.61 per diluted share, contrast with $124 million, or $0.70 per diluted share, in 2014.
Operating earnings for the second quarter 2015 were $137 million, or $0.76 per diluted share, contrast with second quarter 2014 operating earnings of $128 million, or $0.73 per diluted share. Operating earnings exclude non-recurring items, certain mark-to-market adjustments and suspended operations. Reconciliations of stated earnings to operating earnings are comprised of at the end of this news release.
DTE Energy Company operates in the utility operations. The company’s Electric segment engages in the generation, purchase, distribution, and sale of electricity to about 2.1 million residential, commercial, and industrial customers in southeastern Michigan.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
